A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Explore this paper's citation graph
Summary
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping.
- Type
- article
- Published
- 2003-07-31
- Cited by
- 2,835
- References
- 19
- Access
- Open access
- OpenAlex
- https://openalex.org/W2046507292
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8460503
Keywords
Medicine, Placebo, Bevacizumab, Interim analysis, Internal medicine
References
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
- Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.
- Molecular and biological properties of vascular endothelial growth factor
- Mutations of the VHL tumour suppressor gene in renal carcinoma
- Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
- A multiple testing procedure for clinical trials.
- Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state.
- Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice.
- The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
- Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
- Neutralizing anti‐vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
- Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.
- Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
- Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
- Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
- Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
Cited by
- The ras signalling pathway as a target in cancer therapy.
- Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
- Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Overview of monoclonal antibodies in cancer therapy: present and promise.
- Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma
- The ubiquitin-proteasome pathway and its role in cancer.
- An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia.
- Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
- Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
- Cancer du rein : le bout du tunnel ?
- Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status
- Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel
- Variable penetrance of a consensus classification scheme for renal cell carcinoma.
- Adverse effects on hemostatic function of drugs used in hematologic malignancies.
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
- A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRα tyrosine kinase inhibitors: Derivatives of N-Phenyl-N′-4-(4-quinolyloxy)phenylurea as antitumor agents
- New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.
- Case records of the Massachusetts General Hospital. Case 8-2009. A 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum.
- Update on systemic therapies of metastatic renal cell carcinoma
Related papers
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases
- Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes
- P-0183BEVACIZUMAB CAN BE INFUSED SAFELY OVER 10 MINUTES IN METASTATIC COLORECTAL CANCER
- Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
- Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.
- Two cases of leg ulcer caused by bevacizumab
- This Issue At A Glance
- Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma.
- Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
- Comparison of Serum Concentrations of Bevacizumab and Vascular Endothelial Growth Factor (VEGF) Levels in Laser and Bevacizumab Treated ROP Patients